Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Tampa, Florida 33612


Purpose:

The purpose of this study is to find out what effects (good and/or bad) this new cancer vaccine has on the patient and their cancer, whether it is safe and whether it can help get rid of their cancer (malignant melanoma). We want to check how the patient's immune system reacts, both before and after the vaccine treatment.


Study summary:

The vaccine will be made by mixing two kinds of cells: 1) some of the patient's own malignant melanoma cells which were removed by surgery and then processed in the Cell Therapy Laboratory, and 2) experimental "bystander" cells. All the cells in the vaccine will be treated with high-dose X-rays to make sure that none of them grow and cause more cancer. The bystander cells, called "GM.CD40L", are human cells that have been genetically changed. The original cells, called K562, had the genes for human GM-CSF and CD40L inserted into them. These changes are designed to help boost the patient's immune system to better fight the cancer in their body.


Criteria:

Inclusion Criteria: - Histologically confirmed stage IIIC or stage IV melanoma - Measurable disease - Age 18 or older - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - No radiation therapy within 2 weeks prior to first vaccine administration - No chemotherapy within 4 weeks prior to first vaccine administration - No steroid therapy within 4 weeks prior to first vaccine administration - No surgery within 10 days prior to first vaccine administration - Patient's written informed consent - Patient's ability to comply with the visit schedule and assessments required by the protocol - Adequate organ function (measured within a week of beginning treatment): - White blood count (WBC) > 3,000/mm^3 and absolute neutrophil count (ANC) >1500/mm^3 - Platelets > 100,000/mm^3 - Hematocrit > 25% and Hgb > 8 g/dL - Bilirubin < 2.0 mg/dL - Creatinine < 2.0 mg/dL, or creatinine clearance > 60 mL/min Exclusion Criteria: - Symptomatic or untreated brain metastasis - Any serious ongoing infection - Current corticosteroid or other immunosuppressive therapy - Any other pre-existing immunodeficiency condition (including known HIV infection) - Pregnant or lactating women -- Patients in reproductive age must agree to use contraceptive methods for the duration of the study (*A pregnancy test will be obtained before treatment) - ECOG performance status of 2, 3, or 4 - Any second active primary cancer


NCT ID:

NCT00101166


Primary Contact:

Principal Investigator
Sophie Dessureault, M.D., Ph.D.
H. Lee Moffitt Cancer Center and Research Institute


Backup Contact:

N/A


Location Contact:

Tampa, Florida 33612
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.